Xaliproden clinical trials
How each study uses xaliproden is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2003 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2005 | 1 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses xaliproden is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based RegimensTerminatedPhase 3SanofiNCT00603577Written as Xaliproden
- Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.CompletedPhase 3SanofiNCT00305188Written as Xaliproden (SR57746A)
- Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCompletedPhase 3SanofiNCT00104013Written as xaliproden (SR57746A)
- 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCompletedPhase 3SanofiNCT00103649Written as xaliproden (SR57746A)
- XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV ChemotherapyCompletedPhase 3SanofiNCT00272051Written as SR57746A
Codes
What other systems call xaliproden · ClinicalTrials.gg INT004466
- MeSH (NLM) C462299xaliprodenConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) V8QL94KNQOXALIPRODENConfirmed FDA, NLM, Wikidata
- Wikidata Q12745720xaliprodenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152924XaliprodenOne source FDA
- DrugBank DB06393One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C462299 | xaliproden | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | V8QL94KNQO | XALIPRODEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q12745720 | xaliproden | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152924 | Xaliproden | One source FDA |
| DrugBank | DB06393 | — | One source Wikidata |
Also registered as xaliproden hydrochloride (UNII 44D5EE8E26).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.